211 related articles for article (PubMed ID: 34467417)
1. Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype.
Elias EE; Sarapura Martinez VJ; Amondarain M; Colado A; Cordini G; Bezares RF; Fernandez Grecco H; Custidiano MDR; Sánchez Ávalos JC; Garate G; Pavlovsky MA; Borge M; Giordano M; Gamberale R
Cancer Immunol Immunother; 2022 Apr; 71(4):979-987. PubMed ID: 34467417
[TBL] [Abstract][Full Text] [Related]
2. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
Bojarczuk K; Sasi BK; Gobessi S; Innocenti I; Pozzato G; Laurenti L; Efremov DG
Blood; 2016 Jun; 127(25):3192-201. PubMed ID: 27095788
[TBL] [Abstract][Full Text] [Related]
3. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
Haselager MV; Kielbassa K; Ter Burg J; Bax DJC; Fernandes SM; Borst J; Tam C; Forconi F; Chiodin G; Brown JR; Dubois J; Kater AP; Eldering E
Blood; 2020 Dec; 136(25):2918-2926. PubMed ID: 32603412
[TBL] [Abstract][Full Text] [Related]
4. High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.
Oppermann S; Ylanko J; Shi Y; Hariharan S; Oakes CC; Brauer PM; Zúñiga-Pflücker JC; Leber B; Spaner DE; Andrews DW
Blood; 2016 Aug; 128(7):934-47. PubMed ID: 27297795
[TBL] [Abstract][Full Text] [Related]
5. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
6. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054
[TBL] [Abstract][Full Text] [Related]
7. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia.
Sarapura Martinez VJ; Buonincontro B; Cassarino C; Bernatowiez J; Colado A; Cordini G; Custidiano MDR; Mahuad C; Pavlovsky MA; Bezares RF; Favale NO; Vermeulen M; Borge M; Giordano M; Gamberale R
Front Oncol; 2023; 13():1143881. PubMed ID: 37020867
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax.
Avsec D; Škrlj Miklavčič M; Burnik T; Kandušer M; Bizjak M; Podgornik H; Mlinarič-Raščan I
Cell Death Dis; 2022 Oct; 13(10):860. PubMed ID: 36209148
[TBL] [Abstract][Full Text] [Related]
10. Development of venetoclax for therapy of lymphoid malignancies.
Zhu H; Almasan A
Drug Des Devel Ther; 2017; 11():685-694. PubMed ID: 28331288
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia.
Carrà G; Nicoli P; Lingua MF; Maffeo B; Cartellà A; Circosta P; Brancaccio M; Parvis G; Gaidano V; Guerrasio A; Saglio G; Taulli R; Morotti A
J Cell Mol Med; 2020 Jan; 24(2):1650-1657. PubMed ID: 31821686
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
13. IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment.
Shen Y; Crassini K; Fatima N; O'Dwyer M; O'Neill M; Christopherson RI; Mulligan SP; Best OG
Blood Adv; 2020 Oct; 4(20):5093-5106. PubMed ID: 33085757
[TBL] [Abstract][Full Text] [Related]
14. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.
Blunt MD; Koehrer S; Dobson RC; Larrayoz M; Wilmore S; Hayman A; Parnell J; Smith LD; Davies A; Johnson PWM; Conley PB; Pandey A; Strefford JC; Stevenson FK; Packham G; Forconi F; Coffey GP; Burger JA; Steele AJ
Clin Cancer Res; 2017 May; 23(9):2313-2324. PubMed ID: 27697994
[No Abstract] [Full Text] [Related]
15. MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment.
Crassini K; Shen Y; Stevenson WS; Christopherson R; Ward C; Mulligan SP; Best OG
Br J Haematol; 2018 Aug; 182(3):360-372. PubMed ID: 29767411
[TBL] [Abstract][Full Text] [Related]
16. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.
Ten Hacken E; Valentin R; Regis FFD; Sun J; Yin S; Werner L; Deng J; Gruber M; Wong J; Zheng M; Gill AL; Seiler M; Smith P; Thomas M; Buonamici S; Ghia EM; Kim E; Rassenti LZ; Burger JA; Kipps TJ; Meyerson ML; Bachireddy P; Wang L; Reed R; Neuberg D; Carrasco RD; Brooks AN; Letai A; Davids MS; Wu CJ
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282833
[TBL] [Abstract][Full Text] [Related]
17. Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma.
Thus YJ; Eldering E; Kater AP; Spaargaren M
Leukemia; 2022 Sep; 36(9):2165-2176. PubMed ID: 35725771
[TBL] [Abstract][Full Text] [Related]
18. Electron transport chain and mTOR inhibition synergistically decrease CD40 signaling and counteract venetoclax resistance in chronic lymphocytic leukemia.
Chen Z; Cretenet G; Carnazzo V; Simon-Molas H; Kater AP; Windt GJWV; Eldering E
Haematologica; 2024 Jan; 109(1):151-162. PubMed ID: 37439352
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
[TBL] [Abstract][Full Text] [Related]
20. Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies.
Melvold K; Giliberto M; Karlsen L; Ayuda-Durán P; Hanes R; Holien T; Enserink J; Brown JR; Tjønnfjord GE; Taskén K; Skånland SS
Mol Oncol; 2022 Mar; 16(5):1153-1170. PubMed ID: 34861096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
